{"product_id":"biolegend-301602","title":"Biolegend, 301602, Purified anti-human CD11c Antibody, 100μg","description":"\u003cp\u003eCD11c is a 145-150 kD type I transmembrane glycoprotein also known as integrin α X and CR4. CD11c non-covalently associates with integrin β2 (CD18) and is expressed on monocytes\/macrophages, dendritic cells, granulocytes, NK cells, and subsets of T and B cells. CD11c has been reported to play a role in adhesion and CTL killing through its interactions with fibrinogen, CD54, and iC3b.\u003cbr\u003e\n100μg\u003cbr\u003e\nVerified Reactivity: Human, Cynomolgus, Rhesus\u003cbr\u003e\nReported Reactivity: African Green, Baboon, Chimpanzee, Squirrel Monkey\u003cbr\u003e\nAntibody Type: Monoclonal\u003cbr\u003e\nHost Species: Mouse\u003cbr\u003e\nFormulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.\u003cbr\u003e\nPreparation: The antibody was purified by affinity chromatography.\u003cbr\u003e\nConcentration: 0.5 mg\/ml\u003cbr\u003e\nStorage \u0026amp; Handling: The antibody solution should be stored undiluted between 2°C and 8°C.\u003cbr\u003e\nApplication: FC - Quality tested CyTOF® - Verified IHC - Reported in the literature, not verified in house\u003cbr\u003e\nRecommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤2.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.\u003cbr\u003e\nApplication Notes: Clone 3.9 preferentially binds the activated form of CD11c, is specific for the I domain of CD11c, and is able to partially block the binding of CD11c and ICAM-4. 3.9 binding is divalent cation dependent12. While analyzing blood, it is best to use heparin as the anti-coagulant and not EDTA. Since the ability of clone 3.9 to bind to its target is divalent cation dependent, the usage of EDTA as an anti-coagulant may be detrimental to staining due to its chelating properties. Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue sections4, and functional assays5,6. The LEAF™ purified antibody (Endotoxin \u0026lt;0.1 EU\/μg, Azide-Free, 0.2 μm filtered) is recommended for functional assays (Cat. No. 301616). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 301632) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin \u0026lt;0.01 EU\/µg).\u003cbr\u003e\nApplication References(PubMed link indicates BioLegend citation): Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York. Knapp W, et al. 1989. Leucocyte Typing IV Oxford University Press. New York. McMichael A, et al. Eds. 1987. Leucocyte Typing III Oxford University Press. New York. Vainer B, et al. 2000. Am. J. Surg. Pathol. 24:1115. (IHC) Ottonello L, et al. 1999. Blood 93:3505. Metelitsa LS, et al. 2002. Blood 99:4166. Sadhu C, et al. 2007. J. Leukoc. Biol. doi:10.1189\/jlb.1106680. PubMed Ihanus E, et al. 2007. Blood 109:802-810. Gurer C, et al. 2008. Blood 112:1231. PubMed Asai A, et al. 2009. J. Lipid Res. 50:95. PubMed Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC) Sadhu C, et al. 2008. J. Immunoass. Immunoch. 29:42. (FC)\u003cbr\u003e\nProduct Citations: Dallari S, et al. 2017. Nat Commun. 8:14830. PubMed Melo-Gonzalez F, et al. 2018. J Biol Chem. 293:8543. PubMed Ortiz AM, et al. 2018. Nat Med. 24:1313. PubMed Korn MA, et al. 2020. J Immunol. 205:2595. PubMed Gurer C, et al. 2008. Blood. 112:1231. PubMed Santos R, et al. 2017. Nat Commun. . 10.1038\/s41467-017-01760-5. PubMed Sadhu C, et al. 2007. J Leukoc Biol . 81:1395. PubMed Kremenovic M, et al. 2020. Cancers (Basel). 12:. PubMed Mann ER, et al. 2020. Sci Immunol. :5. PubMed Kaufmann M, et al. 2021. Med. 2(3):296-312.e8. PubMed Gonzalez VD, et al. 2021. Cell Reports. 36(9):109632. PubMed Liu X, et al. 2022. STAR Protoc. 3:101310. PubMed Borges TJ, et al. 2018. Nat Commun. 9:3482. PubMed Bruno TC, et al. 2017. Cancer Immunol Res. 0.831944444. PubMed Lukácsi S, et al. 2020. PLoS One. 15:e0232432. PubMed Baskar R, et al. 2022. Cell Rep Methods. 2:. PubMed Eccles JD, et al. 2020. Cell Rep. 30:351. PubMed Roussel M, et al. 2021. Cell Reports Medicine. 2(6):100291. PubMed Asai A, et al. 2009. J Lipid Res. 83:4365. PubMed Kato M, et al. 2021. PLoS One. 16:e0252116. PubMed Delgado-Gonzalez A, et al. 2022. STAR Protoc. 3:101425. PubMed Dinh HQ, et al. 2020. Immunity. 53(2):319-334.e6. PubMed Martin E, et al. 2020. JCI Insight. :5. PubMed\u003cbr\u003e\nRRID: AB_314171 (BioLegend Cat. No. 301601) AB_314172 (BioLegend Cat. No. 301602)\u003cbr\u003e\nStructure: Integrin, type I transmembrane glycoprotein, associates with integrin β2 (CD18), 145-150 kD\u003cbr\u003e\nDistribution: Myeloid, dendritic cells, NK cells, B cells and T cell subsets\u003cbr\u003e\nFunction: Adhesion, CTL killing\u003cbr\u003e\nLigand\/Receptor: CD54, fibrinogen, iC3b, ICAM-1, ICAM-4\u003cbr\u003e\nCell Type: B cells, Dendritic cells, Neutrophils, NK cells, T cells, Tregs\u003cbr\u003e\nBiology Area: Cell Adhesion, Cell Biology, Costimulatory Molecules, Immunology, Innate Immunity, Neuroscience, Neuroscience Cell Markers\u003cbr\u003e\nMolecular Family: Adhesion Molecules, CD Molecules\u003cbr\u003e\nAntigen References: 1. Petty H. 1996. Immunol. Today 17:209. 2. Springer T. 1994. Cell 76:301. 3. Ihanus E, et al. 2007. Blood 109:802-810.\u003cbr\u003e\nGene ID: 3687\u003cbr\u003e\nUniProt: View information about CD11c on UniProt.org\u003cbr\u003e\nClone: 3.9\u003cbr\u003e\nRegulatory Status: RUO\u003cbr\u003e\nWorkshop: III NL707\u003cbr\u003e\nOther Names: Integrin αX subunit, CR4, p150, ITGAX\u003cbr\u003e\nIsotype: Mouse IgG1, κ\u003c\/p\u003e","brand":"Biolegend","offers":[{"title":"Default Title","offer_id":46862333870249,"sku":"301602","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/products\/biolegend-301602","provider":"Iright","version":"1.0","type":"link"}